▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1344 by analyst upside · 2026-08-14
QURE
uniQure N.V.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+47.8%
implied upside to consensus target
Current Price $47.06
Consensus Target $69.57
Bull Target $96.32
Bear Target $46.64
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
8
Hold
1
Sell
0
52-Week Low $8.73
52-Week High $71.5
YTD Return +101.2%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $19M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.73
52-Week High $71.5
Current Price $47.06
Bear Target $46.64
Bull Target $96.32
● Now $47.06 ● Target $69.57
TRADING DATA
Avg Volume 1.9M
YTD Return +101.2%
Analyst Count 11
Consensus Buy
Upside to Target +47.8%
Last Updated 2026-08-14

ANALYST SUMMARY

uniQure N.V. (QURE) is currently trading at $47.06 with a Wall Street consensus price target of $69.57, implying potential upside of 47.8% over the next 12 months. 11 analysts currently cover QURE, with a consensus rating of Buy - 91% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $96.32, while the most cautious has a target of $46.64.

QURE operates in the Healthcare sector with a market capitalisation of $3B. The stock is up 101.2% year-to-date and is currently trading near the upper end of its 52-week range of $8.73 – $71.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OPCH +18.8%
Option Care Health, Inc.
$4B · P/E 18.2x · Buy
INDV +28.2%
Indivior Pharmaceuticals, Inc.
$5B · P/E 13.7x · Buy
VCYT +35.7%
Veracyte, Inc.
$3B · P/E 30.4x · Buy
HRMY +19.7%
Harmony Biosciences Holdings, Inc.
$2B · P/E 12.9x · Buy
TMDX +8.5%
TransMedics Group, Inc.
$3B · P/E 22.5x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for QURE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays ↑ Upgrade
Equal-Weight → Overweight 2026-06-18 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-06-18 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-06-18 29% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-06-18 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-05-06 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-04-30 33% win rate (6 calls)
Goldman Sachs - Reiterated
Neutral → Neutral 2026-04-20 Building track record
Barclays - Reiterated
Equal-Weight → Equal-Weight 2026-03-23 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
19/30
Consensus clarity
9/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →